Vivos Therapeutics, Inc.
VVOS
$2.26
-$0.265-10.52%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -4.79% | 18.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.79% | 18.57% | |||
| Cost of Revenue | 8.77% | -5.33% | |||
| Gross Profit | -11.96% | 36.86% | |||
| SG&A Expenses | 8.80% | -20.34% | |||
| Depreciation & Amortization | 0.69% | -0.68% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.60% | -16.85% | |||
| Operating Income | -36.62% | 48.85% | |||
| Income Before Tax | -35.54% | 48.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -35.54% | 48.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -35.54% | 48.71% | |||
| EBIT | -36.62% | 48.85% | |||
| EBITDA | -39.53% | 50.78% | |||
| EPS Basic | -2.19% | 63.33% | |||
| Normalized Basic EPS | -2.19% | 63.33% | |||
| EPS Diluted | -2.19% | 63.33% | |||
| Normalized Diluted EPS | -2.19% | 63.33% | |||
| Average Basic Shares Outstanding | 32.64% | 39.87% | |||
| Average Diluted Shares Outstanding | 32.64% | 39.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
